Aviptadil acetate is used in research on pulmonary fibrosis, pulmonary arterial hypertension (PAH), and respiratory failure caused by SARS-CoV-2; it induces pulmonary vasodilation, inhibits vascular smooth muscle cell (SMC) proliferation and platelet aggregation; it also demonstrates protective effects against cigarette smoke extract (CSE)-induced cell death in L2 cells, reduces CSE-stimulated matrix metalloproteinase (MMP) activity and caspase-3 activation, and attenuates lipopolysaccharide (LPS)-induced MMP-9 activity and expression in rat alveolar macrophages.